SYSTEMATIC REVIEW article

Front. Neurol.

Sec. Stroke

Volume 16 - 2025 | doi: 10.3389/fneur.2025.1617817

Efficacy and safety of tranexamic acid administration for subarachnoid hemorrhage: A systematic review and meta-analysis

Provisionally accepted
Eriya  ImaiEriya Imai1Hiroshi  ItoHiroshi Ito2Hiromu  OkanoHiromu Okano3*Akihiko  InoueAkihiko Inoue4Takero  TerayamaTakero Terayama5HIROSHI  OKAMOTOHIROSHI OKAMOTO3Toru  HifumiToru Hifumi3Yoshihisa  FujimotoYoshihisa Fujimoto6Gaku  FujiwaraGaku Fujiwara7Yasuhiro  KurodaYasuhiro Kuroda8
  • 1Mitsui Memorial Hospital, Tokyo, Japan
  • 2Osaka University, Suita, Japan
  • 3St. Luke's International Hospital, Tokyo, Japan
  • 4Hyogo Emergency Medical Center, Hyogo, Japan
  • 5Self-Defense Forces Central Hospital, Tokyo, Japan
  • 6St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
  • 7Kyoto University, Kyoto, Kyōto, Japan
  • 8Kagawa University, Takamatsu, Kagawa, Japan

The final, formatted version of the article will be published soon.

Aneurysmal subarachnoid hemorrhage (SAH) carries a high risk of early rebleeding and worsens prognosis. Tranexamic acid (TXA), an antifibrinolytic agent, can prevent rebleeding; however, its effects on mortality and neurological outcomes remain controversial. This review evaluated the efficacy and safety of TXA with SAH. MEDLINE, CENTRAL, EMBASE, ICTRP, and ClinicalTrials.gov were systematically searched for randomized controlled trials (RCTs) and non-randomized studies of interventions (NRSIs) to assess TXA use in SAH. Studies comparing TXA with controls with SAH were included. The primary outcome was the mortality; secondary outcomes included neurological outcomes, rebleeding, thromboembolism, delayed cerebral ischemia (DCI), hydrocephalus, and adverse events. The certainty of evidence was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) approach. Fifteen RCTs (3,109 patients) and nine NRSIs (1,506 patients) were included. RCTs demonstrated that TXA likely does not reduce mortality (risk ratio [RR], 1.00; 95% confidence interval [CI], 0.82–1.22; moderate certainty) and neurological outcome, and may not increase thromboembolism and DCI. However, TXA probably reduces rebleeding but probably increases hydrocephalus. The NRSIs results were similar. Although routine use is not supported, TXA may be considered for high-risk patients when early aneurysm treatment is unavailable. Registeration: Registered in the Open Science Framework (https://osf.io/yp78b/).

Keywords: Meta-analysis, Subarachnoid Hemorrhage, Systematic review, Tranexamic Acid, Rebleeding

Received: 25 Apr 2025; Accepted: 02 Jun 2025.

Copyright: © 2025 Imai, Ito, Okano, Inoue, Terayama, OKAMOTO, Hifumi, Fujimoto, Fujiwara and Kuroda. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Hiromu Okano, St. Luke's International Hospital, Tokyo, Japan

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.